# Itacitinib in Combination With Erlotinib in Non Small Cell Lung Cancer Patients With Epidermal Growth Factor Receptor (EGFR) Activating Mutations

> **NCT02355431** · PHASE2 · WITHDRAWN · sponsor: **Incyte Corporation**

## Conditions studied

- Solid Tumors and Hematologic Malignancy
- NSCLC (Non-small Cell Lung Carcinoma)

## Interventions

- **DRUG:** Itacitinib
- **DRUG:** erlotinib
- **DRUG:** placebo

## Key facts

- **NCT ID:** NCT02355431
- **Lead sponsor:** Incyte Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2014-12
- **Primary completion:** 2015-09
- **Final completion:** 2015-09
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Study withdrawn before enrolling first patient
- **Last updated:** 2019-03-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02355431

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02355431, "Itacitinib in Combination With Erlotinib in Non Small Cell Lung Cancer Patients With Epidermal Growth Factor Receptor (EGFR) Activating Mutations". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT02355431. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*